An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer

BACKGROUND: Nivolumab + ipilimumab + two cycles chemotherapy (N-I + chemo, intensive immunotherapy but chemo-light) and pembrolizumab + chemotherapy (Pem + chemo) were both recommended as first-line treatment for metastatic non-small cell lung carcinoma (NSCLC) patients. We conducted this indirect c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Panpan, Mao, Ziyang, Wang, Qinyang, Jia, Xiaohui, Geng, Luying, Xu, Hong, Jiang, Lili, Yang, Chengcheng, Jiao, Min, Guo, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473819/
https://www.ncbi.nlm.nih.gov/pubmed/34589422
http://dx.doi.org/10.3389/fonc.2021.698199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473819/
https://www.ncbi.nlm.nih.gov/pubmed/34589422
http://dx.doi.org/10.3389/fonc.2021.698199

Ejemplares similares